Capital Empowers Innovation: Vcare PharmaTech Completes Nearly RMB 200 Million Series C3 Financing

　　Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has successfully closed its Series C3 financing totaling nearly RMB 200 million. The round was led by existing shareholder Hongcheng Investment, with follow-on investments from institutions including Xinghe Venture Capital, Hangzhou Jinlong, Hongyao Kechuang and Huadian Investment. Meanwhile, the firm has onboarded high-caliber new investors such as Huafuruixing, consolidating a solid capital foundation for its sustainable long-term growth.

　　Currently Vcare PharmaTech is actively advancing its pre-IPO financing process. Proceeds from the fundraising will be primarily allocated to intensive R&D of core innovative drug candidates, upgrading of its AI-powered technology platform, development of future commercialization systems and global market expansion, enabling a closed-loop industrial chain spanning early-stage drug discovery through to industrialized commercial launch.

　　Going forward, Vcare PharmaTech will keep focusing on unmet clinical needs and devote itself to developing innovative therapies for cardiovascular & cerebrovascular disorders, oncology and autoimmune diseases. Fueled by capital support, the Company will accelerate the translation of R&D breakthroughs into marketable medicines, striving to launch more high-quality, differentiated innovative drugs to benefit patients worldwide and drive high-quality innovative development of the biopharmaceutical industry.

　　About Hongcheng Investment

　　Founded in 2017, Ningbo Hongcheng Private Equity Fund Management Co., Ltd. is an affiliate of Wuchan Zhongda Group Co., Ltd., a Fortune Global 500 enterprise. Serving as the Group’s dedicated equity investment and industrial fund platform for healthcare and biopharma, Hongcheng Investment deploys an integrated “capital + industrial resources” investment strategy across pharmaceutical manufacturing, auxiliary industries, novel drugs and innovative medical devices. It functions as a core vehicle for Wuchan Zhongda to build a synergistic innovation-industry-finance ecosystem. With its first investment in Vcare PharmaTech in 2022, Hongcheng stepped up its backing as the lead investor in this C3 round, expressing full confidence in Vcare’s innovative R&D pipeline and promising commercial prospects.

　　About Huafuruixing

　　Huafuruixing Investment Management Co., Ltd. is a wholly-owned alternative and comprehensive investment arm of Huaan Securities (600909.SH). Positioned as the brokerage’s dedicated equity investment channel linking technological innovation with industrial upgrading, it prioritizes investment in emerging industries including life sciences, next-generation information technology, high-end intelligent equipment, new energy and advanced new materials.

　　About Vcare PharmaTech

　　Established in 2010 by professor from China Pharmaceutical University and overseas returnee pharmaceutical experts, Jiangsu Vcare PharmaTech Co.,Ltd. specializes in the discovery and development of innovative drugs and breakthrough therapeutics. The Company was accredited as a National Key Specialized, Refined, Unique and Innovative “Little Giant” Enterprise in 2025. Headquartered in the Biomedical Valley of Nanjing Jiangbei New Area, Vcare operates a 21,000 ㎡. intelligent R&D hub. It has built a full-spectrum proprietary innovation and industrialization system covering AI-driven differentiated drug discovery and design, preclinical candidate identification, integrated pharmaceutical development and econimic and environmental-friendly production.

　　Boasting a robust talent pool of over 900 employees, more than 84% of its workforce consists of technical R&D staff, among whom over 200 hold master’s or doctoral degrees, forming a highly educated, specialized and innovation-focused core R&D team to underpin continuous technological advancement and product iteration.

　　With 16 years of focused dedication to pharmaceutical innovation, Vcare insists on indigenous R&D and develops differentiated therapies addressing unmet clinical demands. Centered on overcoming drug resistance, boosting therapeutic efficacy and optimizing target selectivity, the Company has assembled a diversified, tiered high-value innovative drug pipeline covering major chronic illnesses such as indications in cardiovascular & cerebrovascular, oncology, inflammatory and autoimmune, etc, in the direction of global commercialization.

　　Its core innovative product pipeline assets feature distinctive competitive edges and clear commercialization outlooks: Eratrectinib (VC004): a next-generation selective TRK small-molecule anti-tumor candidate indicated for NTRK fusion-positive solid tumors across multiple cancer types, currently under regulatory review for marketing approval. Sumecigrel Capsules: a best-in-class oral P2Y12 antagonist selected four times for China’s National Key Science and Technology Projects. It precisely inhibits platelet activation and aggregation to block thrombosis for the prevention and treatment of cardiovascular, cerebrovascular and arterial circulatory disorders, with pivotal confirmatory clinical trials well underway in China. VC005: a new-generation highly selective JAK1 inhibitor under Phase III clinical development for both oral and topical administration against atopic dermatitis across all patient populations. Additional clinical development programs are ongoing for ankylosing spondylitis, vitiligo and alopecia areata, with favorable efficacy and safety data expediting trial progression.

　　Backed by years of technological accumulation, Vcare PharmaTech has established proprietary competitive R&D platforms and received multiple official accreditations including Jiangsu Provincial Engineering Research Center for Innovative Chemical Drugs, Jiangsu Provincial Enterprise Academician Workstation, Jiangsu Postdoctoral Innovation Practice Base and Nanjing Key Laboratory for AI-Aided Drug Design. It also runs a joint postgraduate training center with China Pharmaceutical University, showcasing prominent strengths in industry-university-research integration. The Company has raised aggregate financing exceeding RMB 1.2 billion over the past five years, earning widespread recognition from capital markets.

　　Upholding its founding mission of “The better Care, The better Medicines”, Vcare PharmaTech will persist in original drug innovation, tackle cutting-edge pharmaceutical technologies and expand its global strategic layout. Leveraging robust in-house R&D capabilities to advance differentiated drug candidates, the Company aims to deliver superior therapeutic options for patients worldwide and evolve into a globally influential innovative biopharmaceutical enterprise.